

HEMO ORGANIC LIMITED

CIN - L24231GJ1992PLC018224

Address: Shop 1 to 3, First floor, Piyu Apartment Opp Electricity Sub Station & Mahesh Nagar, Nr. Radhika Chambers & Jay Amarnath Society, Nikol Gam Road, Uttamnagar, Ahmedabad, Gujarat, India – 382 350

Email ID: hemoorganic@gmail.com **Website:** www.hemoorganic.co **Ph. No.** 8238557874

Date: 17th October, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400 001

Dear Sir/Ma'am,

Sub: Outcome of Board Meeting held today i.e., Saturday, 17th October, 2026

Ref: Scrip Code: 524590 | Symbol: HEMORGANIC | ISIN: INE422G01015

The Board of Directors ("the Board") at its meeting held on 17th October, 2026 which commenced at 04:00 p.m. and concluded at 06:30 p.m., has approved and taken on record inter alia:

- a) The Un-audited Standalone Financial Results of the Company for the quarter and half year ended 30th September, 2026 prepared in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, along with Limited Review Report thereon submitted by the statutory auditors.
- b) To transact other businesses as per agenda being circulated.

You are requested to take note of the above.

Thanking You,
Yours faithfully,

For, Hemo Organic Limited

VISHWAMBAR Digitally signed by
KAMESHWAR VISHWAMBAR
SINGH KAMESHWAR SINGH
Date: 2026.10.17
18:53:22 +05'30'

Vishwambar Kameshwar Singh
Managing Director
DIN: 09822587

Hemo Organic Limited

CIN No. L24231GJ1992PLC018224

Registered Office: Shop 1-3, 1 Floor, Piyu apartment, Opp. Electricity sub station, Jay amarnath society, Nikol, Ahmedabad, Gujarat, India, 382350

UNAUDITED FINANCIAL RESULTS (STAND ALONE) FOR THE QUARTER ENDED ON SEPTEMBER 30, 2026

(Rs. in lakhs)


Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
I.	INCOME						
	(a) Revenue from operations	142.90	-	0.01	142.90	0.20	92.90
	(b) Other Income	-	-	-	-	-	0.20
	Total Income	142.90	-	0.01	142.90	0.20	93.10
II.	EXPENSES						
	(a) Purchases of Stock-in-trade	140.00	-	-	140.00	31.14	2.13
	(b) Changes in stock of finished goods, work-in-progress and stock-in-trade	-	-	0.01	-	(30.99)	90.80
	(c) Employee benefit expense	1.56	1.36	1.54	2.92	4.39	6.53
	(d) Finance costs	-	-	-	-	-	-
	(e) Depreciation and amortisation expense	0.01	0.01	0.02	0.02	0.03	0.06
	(f) Other expenses	0.80	6.05	2.56	6.85	11.20	43.41
	Total Expenses (a to g)	142.37	7.42	4.13	149.79	15.77	142.93
III.	Profit before exceptional items and tax (I) - (II)	0.53	(7.42)	(4.12)	(6.89)	(15.57)	(49.83)
IV.	Exceptional Items	-	-	-	-	-	-
V.	Profit before tax (III) - (IV)	0.53	(7.42)	(4.12)	(6.89)	(15.57)	(49.83)
VI.	Tax Expense						
	(a) Current tax	-	-	-	-	-	-
	- Current year	-	-	-	-	-	0.05
	- Prior years	-	-	-	-	-	-
	- MAT Credit (Entitlement)	-	-	(1.03)	-	(3.91)	27.93
	(b) Deferred tax	-	-	(1.03)	-	(3.91)	27.98
	Total tax expense	0.53	(7.42)	(3.09)	(6.89)	(11.66)	(77.81)
VII.	Profit after tax for the period (V) - (VI)						
VIII.	Other comprehensive income						
	Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Remeasurement of the defined benefit liabilities	-	-	-	-	-	-
	Equity instruments through other comprehensive income	-	-	-	-	-	-
	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Other comprehensive income, net of tax	0.53	(7.42)	(3.09)	(6.89)	(11.66)	(77.81)
IX.	Total comprehensive income for the period						
		686.59	346.59	346.59	686.59	346.59	346.59
X.	Paid up equity share capital (Face value of Rs. 10 each)						(439.55)
XI.	Reserves i.e. Other Equity						
XII.	Earnings per equity share (Face value of Rs. 10 each)						
	(1) Basic	0.01	(0.21)	(0.09)	(0.19)	(0.34)	2.24
	(2) Diluted	0.01	(0.21)	(0.09)	(0.19)	(0.34)	2.24

Date: 17/10/2026
Place: Ahmedabad



By order of the Board
Hemo Organic Limited

Vishwambar Singh
DIN : 09822587
Managing Director

STATEMENT OF ASSETS AND LIABILITIES			(Rs. in lakhs)
Particulars	As at 30th September 2026	As at 31st March 2026	
ASSETS			
1) Non-current assets			
(a) Property, Plant and Equipment	0.27	0.29	
(b) Capital work-in-progress	-	-	
(c) Intangible assets under development	-	-	
(d) Financial Assets	-	-	
(i) Investments	-	-	
(ii) Loans	-	-	
(iii) Other Financial Assets	-	-	
(e) Deffered Tax Assets	-	-	
(f) Other Non - Current Assets	-	-	
2) Current assets			
(a) Inventories	50.83	50.83	
(b) Financial Assets	-	-	
(i) Trade receivables	235.76	238.86	
(ii) Cash and cash equivalents	1.28	1.09	
(iii) Bank balances other than (ii) above	-	-	
(iv) Loans	77.07	86.18	
(v) Other Financial Assets	-	-	
(c) Current tax assets	0.05	-	
(d) Other current assets	110.54	68.86	
Total Assets	475.80	446.11	
EQUITY AND LIABILITIES			
Equity			
(a) Equity Share capital	686.59	346.59	
(b) Money received against share warrents	-	106.25	
(c) Other Equity	(361.44)	(439.55)	
LIABILITIES			
1) Non-current liabilities			
(a) Financial Liabilities	-	-	
(i) Borrowings	129.11	274.06	
(ii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-	
(b) Provisions	-	-	
(c) Deferred tax liabilities (Net)	0.05	0.05	
2) Current liabilities			
(a) Financial Liabilities	-	-	
(i) Borrowings	-	-	
(ii) Trade payables	19.22	156.12	
(iii) Other financial liabilities	1.41	1.41	
(b) Other current liabilities	0.56	0.58	
(c) Provisions	0.30	0.60	
(d) Current Tax Liabilities (Net)	-	-	
Total Equity and Liabilities	475.80	446.11	
Date: 17/10/2026 Place: Ahemdabad			
			
By order of the Board Hemo Organic Limited  Vishwambar Singh DIN : 09822587 Managing Director			

Cash flow Statement For the period ended 30th September,2026

(Rs. in lakhs)

Sr No.	Particulars	For the half year ended September, 2026	For the year ended September, 2025
A.	Cash flow from operating activites		
	Net profit before tax	(6.89)	(15.57)
	Non Cash Income	-	-
	Depreciation	0.02	0.02
	Operating profit before working capital changes	(6.87)	(15.55)
	Net Changes in :-		
	(Increase)/ decrease in Operating Assets:		
	- Inventories	-	(30.99)
	- Trade Receivables	3.10	(0.07)
	- Other Non - Current Assets	-	-
	- Other Current Assets	(41.73)	(2.39)
	Increase/ (decrease) in other current liabilities		
	- Long - Term Provisions	-	-
	- Trade Payables	(136.90)	31.92
	- Short - Term Provisions	(0.30)	(0.30)
	- Other Financial Liabilities	-	-
	- Other Current Liabilities	(0.02)	0.57
	Cash generated from operations	(182.72)	(16.81)
	Income tax paid	-	-
	Net cash inflow/(outflow) from operating activities (A)	(182.72)	(16.81)
B.	Cash flow from investing activites		
	- Payments for Property,Plant & Equipments	-	(0.15)
	- Decrease in Loans & Advances	9.11	-
	Net cash inflow / (outflow) from investing activities (B)	9.11	(0.15)
C.	Cash inflow/(outflow) from financing activities		
	- Repayment of borrowings	-	-
	- Increase in Equity Share capital	318.75	-
	- Financial expenses	-	-
	- Loan Taken	(144.95)	16.14
	Net cash inflow / (outflow) used in financing activities (C)	173.80	16.14
	Net changes in cash and cash equivalents (A+B+C)	0.19	(0.82)
	Opening Cash and cash equivalents	1.09	0.87
	Closing Cash and cash equivalents	1.28	0.05

Date: 17/10/2026
Place: Ahemdabad



By order of the Board
Hemo Organic Limited

Vishwambar Singh
DIN : 09822587
Managing Director

Notes :

- 1 The Company operates in a single segment . As per Ind AS 108 on segment reporting issued by the ICAI, the same is considered to constitute as single primary segment. Accordingly, the disclosure requirements of Ind AS 108 are not applicable.
- 2 The above standalone financial results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 17 Oct, 2026.
- 3 The financial results of the company have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the companies Act, 2013 read with relevant rules there under and in terms with regulation 33 of SEBI (Listing Obligation and Disclosures Requirements) regulations 2015 and SEBI circular dated 5th July 2016.
- 4 Earning per share for the quarter and year ended has been calculated as per weighted average formula and diluted Earning per share has been calculated considering proposed issue of equity shares on account of conversion of convertible securities.
- 5 Previous period figures have been regrouped and rearranged, whenever considered necessary.
- 6 There are no associates, subsidiaries, joint ventures of the company and hence consolidated results are not applicable.

Date: 17/10/2026

Place: Ahemdabad



**By order of the Board
Hemo Organic Limited**

A handwritten signature in blue ink, appearing to read "Vishwambar Singh".

**Vishwambar Singh
DIN : 09822587
Managing Director**

INDEPENDENT AUDITOR'S REVIEW REPORT

Limited Review Report on Standalone Quarter & half year Ended as on 30th September, 2026 Unaudited Financial Results of the company pursuant to Regulation 33 of the SEBI (listing Obligation and Disclosure Requirements) Regulations, 2015.

To,

The Board of Directors,
HEMO ORGANIC LIMITED

We have reviewed the accompanying statement of unaudited financial results of M/s HEMO ORGANIC LIMITED for the quarter ended 30th September, 2026, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FCA/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, except as specified in Qualified Opinion para, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and



Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Qualified Opinion:

1. We have not been provided with the balance confirmation or any other details for the trade receivable & trade payable in the books of accounts & in the absence of the same we are unable to confirm the balance and nature of the transactions.

Date: 17/10/2026
Place: Ahmedabad



UDIN: 26138132TUZRET5133

For, V S S B & Associates
Chartered Accountants
Firm Registration No. 121356W

Shridhar

Shridhar Shah
Partner
Membership No. 138132